

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to:  
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: June 5, 2006

Signature: \_\_\_\_\_

(Rebecca Butler-Quinan)

Docket No.: 69137-00003USPX  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Dorian Bevec

Application No.: 10/517125

Confirmation No.: N/A

Filed: December 1, 2004

Art Unit: N/A

For: USE OF COMPOUNDS HAVING THE  
BIOLOGICAL ACTIVITY OF  
VASOACTIVE INTESTINAL PEPTIDE FOR  
THE TREATMENT OF SARCOIDOSIS

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application in accordance with 37 CFR 1.98(a)(2). Applicant submits herewith copies of any cited non-patent documents and foreign patent documents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing

of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 10-0447, under Order No. 69137-00003USPX. A duplicate copy of this paper is enclosed.

Dated: June 5, 2006

Respectfully submitted,

By 

Ross T. Robinson

Registration No.: 47,031

JENKENS & GILCHRIST, A PROFESSIONAL  
CORPORATION

1445 Ross Avenue, Suite 3700

Dallas, Texas 75202

(214) 855-4500

Attorneys For Applicant

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/517125
				Filing Date	December 1, 2004
				First Named Inventor	Dorian Bevec
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	69137-00003USPX

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1*	US-3,880,826	04-29-1975	Said et al.
	A2*	US-4,179,337	12-18-1979	Davis et al.

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
	B1	WO-9106565	01-25-1995	Fett Wissenschaft Technology, Fat Science	abs
	B2	WO-9527496	10-19-1995	Proteinix Company	
	B3	WO-9735561	10-02-1997	The Board of Trustees of the University of Illinois	
	B4	EP-0536741	04-14-1995	F. Hoffmann-La Roche AG	
	B5	EP-0204447	10-30-1991	Eye Research Institute of Retina Foundation	
	B6	EP-0405242	10-30-1991	Eye Research Institute of Retina Foundation	
	B7	EP-0463450	02-16-1994	Sanwa Kagaku Kenyusho Co., Ltd.	
	B8	EP-0613904	09-07-1994	0663406	
	B9	EP-0663406	07-19-1995	Sanwa Kagaku Kenyusho Co., Ltd.	
	B10	EP-0620008	09-06-1994	Yeda Research and Development Company, Ltd.	
	B11	WO-8905857	06-29-1989	Trion Forsking-OCH Utvecklings AB	
	B12	WO-9729126	08-14-1997	F. Hoffman-LA Roche, AG	
	B13	EP-0325044	07-26-1989	Beecham Group, PLC	
	B14	EP-0225020	06-10-1987	Beecham Group, PLC	
	B15	EP-0184309	06-11-1986	Beecham Group, PLC	
	B16	EP-0401384	03-13-1996	Kirin-Amegen, Inc.	
	B17	WO-0116295	08-03-2001	The Regents of the University of California	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Hultgardh et al.; "Growth-inhibitory properties of vasoactive intestinal polypeptides."; Regul. Pept.; pg 267-274; 1998.	
	C2	Ishihara et al.; "Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide."; Nueron 8; pg. 811-819; 1992.	
	C3	Moody et al.; Proceedings of the National Academy of Science, USA, 90; pg. 4345; 1992.	
	C4	Wollman et al.; Brain Research 624; pg. 339; 1993.	
	C5	Maruno et al.; "VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells."; American Journal of Physiology 268; pg. L1047-1051; 1995.	
	C6	Said, S. I.; "Vasoactive intestinal polypeptide (VIP) in asthma."; Annals New York Academy of Science, 629; pg. 305-318; 1991.	
	C7	Hamasaki et al.; "Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1."; Journal of Applied Physiology, 54; pg. 1607-1611;	
Examiner Signature			Date Considered

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/517125
				Filing Date	December 1, 2004
				First Named Inventor	Dorian Bevec
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	69137-00003USPX

		1982.	
C8	Inabuchi et al.;	"Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung."; Respiration, 64; pg. 54-58; 1997.	
C9	Saga et al.;	"Vasoactive intestinal peptide relaxes strips of human bronchus, pulmonary artery, and lung parenchyma."; Trans Association of American Physicians, 97; pg. 304-310; 1984.	
C10	Raderer et al.	"123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer."; British Journal of Cancer, 78; pg. 1-5; 1998.	
C11	Raderer et al.;	"Iodine-123-vasoactive intestinal receptor scanning in patients with pancreatic cancer."; Journal of Nuclear Medicine, 39; pg. 1570-1575; 1998.	
C12	Raderer et al.;	"Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111) In-DTPA-D-Phe-octreotide in 194 carcinoid patients."; Vienna University Experience 1993-1998; Journal of Clinical Oncology, 18; pg. 1331-1336; 2000.	
C13	Virgolini et al.;	"Vasoactive intestinal peptide receptor scintigraphy."; Journal of Nuclear Medicine, 36; pg. 1732-1739; 1995.	
C14	Sada et al.;	Journal of Fermentation Bioengineering, 71; pg. 137-139; 1999.	
C15	Newman et al.;	"Sarcoidosis"; New England Journal of Medicine, 336; pg 1224-1234; 1997.	
C16	Chesnutt, A. N.;	"Enigmas in Sarcoidosis"; Western Journal of Medicine, 162; pg. 519-526; 1995.	
C17	Crystal et al.;	"Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts)"; New England Journal of Medicine, 310; pg. 154-166; 1984.	
C18	Winterbauer et al.;	"Use of pulmonary function tests in the management of sarcoidosis."; Chest Journal, 78; pg. 640-647; 1980.	
C19	Muther et al.;	"Renal manifestations of sarcoidosis."; Archive of Internal Medicine, 141; pg. 643-645; 1981.	
C20	DeRemee;	"Sarcoidosis"; Mayo Clinic Proceedings, 70; pg. 177-181; 1995.	
C21	Sharma et al.;	"Myocardial Sarcoidosis"; Chest Journal, 103; pg. 253-258; 1993.	
C22		"Remedy for dermal ulcer - comprises vasoactive intestinal polypeptide as active component"; Derwent, XP002249383.	
C23	Dey et al.;	"Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats, and human subjects." Veterans Administration Medical Center, Dallas, Texas. Cell Tissue Res (1981) 220:231-238.	
C24	Abuchowski et al.;	"Soluble Polymer-Enzyme Adducts." Rutgers University, New Brunswick, New Jersey. 1981, pg. 367-383	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Application No. (if known): 10/517125

Attorney Docket No.: 69137-00003USPX

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on June 5, 2006

Date

Signature

Rebecca Butler-Guinan

Typed or printed name of person signing Certificate

Registration Number, if applicable

(214) 855-4500

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (47 References) (2 pages)